Pfizer Surpasses Q1 Earnings Expectations, Boosted by New and Established Drugs

Pfizer reported first-quarter earnings and revenue that exceeded Wall Street forecasts, driven by growth in recently launched and acquired products alongside steady demand for established drugs like Eliquis. Despite significant declines in Covid vaccine and antiviral pill sales, the company reaffirmed its 2026 financial outlook.

This performance highlights Pfizer's strategic shift towards diversifying its portfolio beyond Covid-related treatments, focusing on long-term investments such as its $10 billion acquisition of obesity biotech Metsera and promising pipeline developments, including a targeted lung cancer drug.

Strong Q1 Results Beat Analyst Expectations

Pfizer posted adjusted earnings per share of 75 cents, surpassing the 72 cents expected by analysts. Revenue reached $14.45 billion, a 5% increase year-over-year and well above the $13.79 billion forecast. Net income stood at $2.69 billion, or 47 cents per share, slightly down from the previous year's $2.97 billion.

New and Established Drugs Offset Covid Sales Decline

Sales of Pfizer's Covid vaccine and antiviral pill Paxlovid fell sharply, with revenues dropping 59% and 62% respectively, missing analyst estimates. However, blockbuster drugs like the blood thinner Eliquis saw a 13% sales increase to $2.17 billion, beating expectations. Other products, including the targeted cancer drug Padcev and the respiratory syncytial virus vaccine, also posted strong growth.

• Eliquis sales rose 13% to $2.17 billion
• Padcev revenue increased 39% to $591 million
• Respiratory syncytial virus vaccine sales grew 37% to $180 million
• Newly launched and acquired products grew 22% operationally

Strategic Investments and Pipeline Focus

To counteract declining Covid product sales and patent expirations, Pfizer is investing heavily in its pipeline and acquisitions. The recent $10 billion purchase of Metsera, an obesity biotech, exemplifies this strategy. The company is also awaiting critical late-stage trial results for an experimental lung cancer drug, signaling a focus on innovative therapies.

Outlook and Market Challenges Ahead

Pfizer reaffirmed its 2026 outlook, projecting adjusted earnings per share between $2.80 and $3 and revenues ranging from $59.5 billion to $62.5 billion, slightly below 2025 levels. The company anticipates a $1.5 billion year-over-year revenue decline from Covid products and another $1.5 billion drop due to loss of exclusivity on certain drugs, including competition for its pneumonia vaccine Prevnar.

“Sales of recently launched and acquired products grew 22% operationally during the quarter,” Pfizer stated, underscoring its successful diversification efforts.—Pfizer

Looking Forward: Innovation and Patent Protection

Pfizer recently secured extended U.S. patent protection for Vyndamax, a treatment for a rare heart condition, until 2031, providing a competitive edge. The company’s focus on innovation and strategic acquisitions aims to sustain growth amid evolving market dynamics and increased competition.